The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain
Bronwyn Bebee, David M Taylor, Elyssia Bourke, Kimberley Pollack, Lian Foster, Michael Ching, Anselm Wong
MEDICAL JOURNAL OF AUSTRALIA | WILEY | Published : 2021
OBJECTIVE: To assess the analgesic efficacy and safety of single-dose oral cannabidiol (CBD) as an adjunct to standard care for patients presenting to an emergency department with acute low back pain. DESIGN: Randomised, double blinded, placebo-controlled clinical trial. SETTING: The tertiary emergency department of Austin Hospital, Melbourne. PARTICIPANTS: Patients who presented with acute, non-traumatic low back pain between 21 May 2018 and 13 June 2019. INTERVENTION: One hundred eligible patients were randomised to receiving 400 mg CBD or placebo in addition to standard emergency department analgesic medication. MAIN OUTCOME MEASURES: Pain score two hours after administration of study age..View full abstract
Awarded by National Health and Medical Research Council fellowship
We thank the staff of the Austin Hospital emergency department for their assistance with the study, and the Robert C. Bulley Charitable Fund and the Austin Medical Research Foundation for funding the CANBACK trial. Anselm Wong holds a National Health and Medical Research Council fellowship (1159907).